Abivax 2025 Net Loss Widens

MT Newswires Live
03/24

Abivax (ABVX) reported full-year 2025 net loss late Monday of 336.1 million euros ($390.4 million), widening from a loss of 176.2 million euros a year earlier.

As of Dec. 31, the company had cash and cash equivalents of 530.4 million euros, expected to fund operations into Q4 2027.

Sofinnova Partners, represented by Kinam Hong, stepped down from the board last week, the company added.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10